2023-09-16 18:24:00
Two hundred and nineteen patients participated in the study proposed by the French company Ose Immunotherapeutics. This was carried out in nine European countries as well as in the United States.
Supporting figures
And vaccine therapeutic developed by the French company Ose Immunotherapeutics shows positive results in the treatment of lung cancer. The study indeed reveals a significant reduction in the risk of death compared to chemotherapy. The results of the clinical trial were announced by Nicolas Poirier, the general director of the company and the results were published in the journal Annals of Oncology. “One year following the start of treatment, 44.1% of patients treated with the vaccine were still alive, while in the group receiving chemotherapy this figure was only 27.5%”indicates the article relayed by Franceinfo. In addition, Professor Benjamin Besse, director of clinical research at the Gustave-Roussy Institute, emphasizes that the vaccine also helps improve patients’ quality of life by reducing side effects compared to chemotherapy.
Avenues to explore
The study involved 219 patients in nine European countries as well as the United States. These results offer avenues for identifying patients who might benefit from this therapeutic vaccine, if it was marketed. These are mainly patients who initially responded to immunotherapy before relapsing, explained Benjamin Besse. The role of therapeutic vaccines once morest cancer is to educate the immune system so that it can specifically recognize and destroy cancer cells. A method which thus opens up new perspectives in the fight once morest lung cancer.
See our file on cancer
???? We are pleased to announce that positive data from the Phase 3 clinical trial evaluating TEDOPI, our therapeutic vaccine for non-small cell lung cancer, has been published in the journal Annals of Oncology. ???? https://t.co/GeoFLu4N6h pic.twitter.com/ujdjcBaYht
— OSE Immunotherapeutics – Biotechs & immunotherapy (@OSEImmuno) September 11, 2023
1694895505
#Lung #cancer #promising #results #obtained #therapeutic #vaccine #LINFO.re
